Northcoast Research Comments on Henry Schein Inc.’s Q2 2017 Earnings (HSIC)
Henry Schein Inc. (NASDAQ:HSIC) – Investment analysts at Northcoast Research lifted their Q2 2017 earnings per share estimates for shares of Henry Schein in a note issued to investors on Tuesday. Northcoast Research analyst E. Snyder now anticipates that the firm will post earnings of $1.78 per share for the quarter, up from their prior estimate of $1.77. Northcoast Research also issued estimates for Henry Schein’s Q3 2017 earnings at $1.85 EPS, Q4 2017 earnings at $2.06 EPS and FY2017 earnings at $7.28 EPS.
A number of other equities analysts have also recently weighed in on HSIC. Credit Suisse Group AG reaffirmed a “hold” rating on shares of Henry Schein in a report on Saturday, June 4th. Zacks Investment Research cut Henry Schein from a “buy” rating to a “hold” rating in a report on Tuesday, July 5th. Finally, Bank of America Corp. began coverage on Henry Schein in a report on Monday, September 12th. They issued a “buy” rating and a $185.00 price target for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $157.84.
Henry Schein (NASDAQ:HSIC) traded up 1.14% during midday trading on Thursday, hitting $162.98. The stock had a trading volume of 541,252 shares. The company has a market cap of $13.33 billion, a PE ratio of 27.61 and a beta of 1.03. The firm has a 50-day moving average of $162.83 and a 200-day moving average of $170.65. Henry Schein has a 12-month low of $134.75 and a 12-month high of $183.00.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.01. The business earned $2.87 billion during the quarter, compared to analyst estimates of $2.85 billion. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period last year, the company earned $1.46 EPS.
Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Henry Schein by 2.2% in the second quarter. Vanguard Group Inc. now owns 7,493,463 shares of the company’s stock valued at $1,324,844,000 after buying an additional 161,065 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Henry Schein by 2.4% in the second quarter. BlackRock Fund Advisors now owns 2,369,132 shares of the company’s stock valued at $418,863,000 after buying an additional 55,384 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Henry Schein by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,342,943 shares of the company’s stock valued at $404,462,000 after buying an additional 8,593 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Henry Schein by 16.5% in the second quarter. Janus Capital Management LLC now owns 2,027,848 shares of the company’s stock valued at $358,522,000 after buying an additional 286,929 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Henry Schein by 55.7% in the second quarter. UBS Asset Management Americas Inc. now owns 802,401 shares of the company’s stock valued at $141,865,000 after buying an additional 286,976 shares during the last quarter. Institutional investors and hedge funds own 91.98% of the company’s stock.
In other news, Director Paul Brons sold 3,381 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $164.03, for a total value of $554,585.43. Following the completion of the sale, the director now directly owns 13,715 shares in the company, valued at $2,249,671.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.27% of the stock is owned by insiders.
Henry Schein Company Profile
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.